Navigation Links
ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Date:9/1/2010

SAN DIEGO, Sept. 1 /PRNewswire/ -- ReVision Therapeutics Inc. today announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration (AMD).

The data, presented Monday by Alexander M. Eaton, M.D., at the Annual Meeting of the American Society of Retinal Specialists, also showed a trend for reduced GA lesion growth rates in patients receiving fenretinide. These data suggest that fenretinide may have an effect on both GA lesion size as well as the conversion to the more sight-threatening wet form of AMD. Fenretinide is the first oral therapeutic to complete a Phase 2 trial in GA patients.

"These results are very exciting as there are currently no drug therapies for geographic atrophy, and there are no treatments for the prevention of CNV," said Dr. Eaton, who was an investigator in the trial. "We are hopeful that the complete analysis will further validate these findings as fenretinide could slow vision loss in the millions of Americans who face blindness because of this disease."

The double-masked, placebo-controlled, multicenter, Phase 2b study evaluated 246 patients with GA. Patients were randomized into three cohorts and received once-daily doses of 100 mg or 300 mg of fenretinide or placebo for 24 months. Retinal lesion size was measured by color fundus photography, fundus autofluorescence and fluorescein angiography. Patients were also evaluated by contrast sensitivity, reading rate, visual acuity, optical coherence tomography, and the incidence of CNV.

Fenretinide was well tolerated with no severe drug-related adverse events and no significant effects on normal vision function.

At the conclusion of the two-year study, 15 of 82 patients (18.3 percent) in the placebo arm progressed to CNV, while 15 o
'/>"/>

SOURCE ReVision Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
2. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
3. Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
4. Cord Blood America Says Debt Reduced $4.194 Million in 2009
5. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
6. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
7. The toxicity of antimicrobial silver in products can be reduced
8. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
9. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
10. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
11. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., a ... drugs for diseases of the central nervous system, today ... chief executive officer, will present at the 33 rd ... will take place at 3:00 p.m. PST on Tuesday, ... San Francisco, Calif. ...
(Date:12/19/2014)... 2014 Research and Markets ( ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research ... a detailed assessment on technological advancements and market ... 1. The Smart Fabrics market is ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for Research ... in the Neurosciences (CEN), and professor of pharmacology at ... a member of the prestigious Dana Alliance for Brain ... to receive this honor. , The Dana Alliance ... Dana Foundation. Its mission is to advance public ...
(Date:12/19/2014)... 19, 2014 The empty capsules ... rising ageing population and technological innovations in the ... industries are catalysing the growth of the empty ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , The ... as new entrants/smaller firms to gauge the pulse ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) ... PX-478, pharmacodynamic studies of PX-12 and preclinical studies ... of the American Association,for Cancer Research (AACR) in ... currently conducting a Phase 1 clinical trial of ...
... April 10 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... a productive,meeting with the U.S. Food and Drug ... Drug Application (NDA) in the third quarter of ... treat mild-to-moderate,community acquired pneumonia (CAP)., (Logo: ...
... Becoming a Global Leader in ... ... 10 ,Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Millennium,Pharmaceuticals, Inc. ... definitive agreement pursuant to which Takeda will acquire,Millennium for approximately $8.8 ...
Cached Biology Technology:Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin 2Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 2Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 4Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 5Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 6Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 7
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... and Biomedical Innovation, studied the socioenvironmental drivers of suicide rates ... coupled with spikes in unemployment were significant risk factors for ... has helped to pinpoint who and when people might be ... that when the difference of the monthly average temperature in ...
... recent years that asthma comes in several variations, with ... These subtypes of asthma can be identified by knowing ... in patients, airways. That information can, in turn, help ... inspire research to better understand, manage, and possibly prevent ...
... to drive people daffy. It,s one of the smallest and ... ponds and small lakes. But it,s also been exploited to ... Now, the genome of Greater Duckweed ( Spirodela polyrhiza ) ... a big boost. In a paper published February 19, 2014 ...
Cached Biology News:Climate change linked to increase in Australia's suicide rates: QUT study 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
...
Biology Products: